ClinicalTrials.gg
CompletedNCT06890416PISSARROUpdated Nov 6, 2025

A Study to Evaluate the Safety and Immunogenicity of RSVpreF Coadministered With Herpes Zoster Vaccine in Adults

A Phase 3 interventional study of RESPIRATORY SYNCYTIAL VIRUS PREFUSION F SUBUNIT VACCINE and HZ/su VACCINE in Respiratory Syncytial Virus (RSV), sponsored by Pfizer. Completed at 26 sites in 2 countries. Open to participants aged 50 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-11-06.

Sponsored by Pfizer · Phase 3, Interventional, and Prevention

From the registry’s dates

  • Primary completion was Sep 2025, 1 year 1 month ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
526
Allocation
Randomized
Ages
50 Years and older
Sex
All
01

Study summary

This purpose of this phase 3 multicenter, parallel-group, open-label study is to learn about the safety, tolerability, and immunogenicity of RSVpreF and HZ/su vaccine when given together in adults 50 years of age and older.

02

Conditions studied

  • Respiratory Syncytial Virus (RSV)

Keywords

  • RSV
  • Vaccine
03

In context

Lead sponsor

Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.

Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
50 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male and female participants 50 years of age and older who are healthy or with stable chronic medical conditions

Exclusion criteria

Exclusion Criteria

  • Current clinically suspected or polymerase chain reaction (PCR)-confirmed ongoing episode of HZ and/or history of clinically suspected or PCR-confirmed HZ within the past 12 months.
  • Prior history of any subtype of Guillain Barré syndrome of any etiology.
  • Serious chronic disorder, including , end-stage renal disease with or without dialysis, clinically unstable cardiac disease, or any other disorder that, in the investigator's opinion, excludes the participant from participating in the study.
  • individuals with known or suspected immunodeficiency, as determined by history and/or laboratory/physical examination, and medication list
  • Previous vaccination with any licensed or RSV vaccine at any time prior to enrollment, or planned receipt of a nonstudy RSV vaccine during study participation.
  • Previous vaccination with any licensed recombinant adjuvant zoster vaccine (Shingrix) at any time prior to enrollment, or planned receipt of a nonstudy licensed VZV vaccine (Shingrix) during study participation.
  • History of previous vaccination with live HZ vaccine (Zostavax) in the last 2 years from enrollment, or planned receipt through study participation.
  • Previous vaccination with any investigational VZV vaccine at any time prior to enrollment, or planned receipt of a nonstudy investigational VZV vaccine during study participation.
  • Individuals who receive chronic systemic treatment with immunosuppressive therapy, including cytotoxic agents, immunosuppressive monoclonal antibodies, systemic (defined as ≥20 mg/day of prednisone or equivalent for ≥14 days), eg, for cancer or an disease, or radiotherapy, from 60 days before study intervention administration, or planned receipt throughout the study.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
526 participants (actual)

Study arms

  • Other
    Coadministration Group

    * Visit 1 (Day 1): RSVpreF + HZ/su dose 1 * Visit 3 (Month 2): HZ/su dose 2

    Biological: RESPIRATORY SYNCYTIAL VIRUS PREFUSION F SUBUNIT VACCINE · Biological: HZ/su VACCINE

  • Other
    Sequential Administration Group

    * Visit 1 (Day 1): HZ/su dose 1 * Visit 2 (Month 1): RSVpreF * Visit 3 (Month 2): HZ/su dose 2

    Biological: RESPIRATORY SYNCYTIAL VIRUS PREFUSION F SUBUNIT VACCINE · Biological: HZ/su VACCINE

Interventions

06

What researchers measure

Primary outcomes

  1. Geometric Mean Ratio (GMR) of Neutralizing Titer (NTs) for RSV A and B in RSVpreF + herpes zoster subunit vaccine (HZ/su) Compared to RSVpreF Alone

    Time frame: 1 month after vaccination with RSVpreF in the RSVpreF + HZ/su coadministration group to RSVpreF alone in the sequential administration group

  2. Anti-gE antibody concentrations expressed as Geometric Mean Concentration (GMC) ratios in RSVpreF + HZ/su Compared to HZ/su Alone

    Time frame: 1 month after the second dose of HZ/su in the RSVpreF + HZ/su coadministration group to HZ/su alone in the sequential administration group

  3. Percentage of Participants reporting Local Reactions Within 7 Days after Vaccination

    Describe local reactions (redness, swelling, and pain at the injection site) within 7 days following each study intervention administration recorded by participants in an electronic diary (e-diary).

    Time frame: Within 7 Days after each vaccination (Vaccination on Day 1)

  4. Percentage of Participants with Systemic Events Within 7 Days after Vaccination

    Describe systemic events (fatigue, headache, vomiting, nausea, diarrhea, muscle pain, and joint pain) within 7 days following each study intervention administration recorded by participants in an electronic diary (e-diary).

    Time frame: Within 7 Days after each vaccination (Vaccination on Day 1)

  5. Percentage of Participants with Adverse Events (AEs)from Vaccination through 1 Month after Vaccination

    Describe AEs occurring through 1 month after each study intervention administration

    Time frame: Within 1 Month after last vaccination

  6. Percentage of Participants with Serious Adverse Events (SAEs) Throughout the Study

    Describe SAEs occurring through 4 months after the first study intervention administration.

    Time frame: Within 4 Months after first study vaccination (Vaccination on Day 1)

Secondary outcomes

  1. NTs for RSV A and RSV B expressed as Geometric Mean Titers (GMT)

    Time frame: Before vaccination with RSVpreF, 1 month after vaccination with RSVpreF

  2. NTs for RSV A and RSV B expressed as Geometric Mean Fold Rise (GMFR)

    Time frame: Before vaccination and 1 month after vaccination with RSVpreF

  3. NTs for RSV A and RSV B expressed as seroresponse rate

    Time frame: 1 month after vaccination with RSVpreF

  4. Anti-gE antibody concentrations expressed as GMCs

    Time frame: Before vaccination and 1 month after the second dose of HZ/su

  5. Anti-gE antibody concentrations expressed as GMFRs

    Time frame: Before vaccination and 1 month after the second dose of HZ/su

  6. Anti-gE antibody concentrations expressed as seroresponse rate

    Time frame: 1 month after the second dose of HZ/su

07

Study locations

26 sites
  • Central Research Associates
    Birmingham, Alabama 35205, United States
  • Medical Affiliated Research Center
    Huntsville, Alabama 35801, United States
  • AMR Clinical
    Mobile, Alabama 36608, United States
  • Kaiser Permanente
    Los Angeles, California 90027, United States
  • Diablo Clinical Research, Inc.
    Walnut Creek, California 94598, United States
  • Alliance for Multispecialty Research, LLC
    Doral, Florida 33172, United States
  • Proactive Clinical Research,LLC
    Fort Lauderdale, Florida 33308, United States
  • De La Cruz Research Center, LLC
    Miami, Florida 33184, United States
  • Centricity Research Columbus Georgia Multispecialty
    Columbus, Georgia 31904, United States
  • Clinical Research Atlanta
    Stockbridge, Georgia 30281, United States
  • Synexus Clinical Research US, Inc.
    Chicago, Illinois 60602, United States
  • Optimal Research
    Peoria, Illinois 61614, United States
  • DelRicht Research
    New Orleans, Louisiana 70115, United States
  • Jadestone Clinical Research
    Silver Spring, Maryland 20904, United States
  • Oakland Medical Research
    Troy, Michigan 48085, United States
  • Clinical Research Professionals
    Chesterfield, Missouri 63005, United States
  • IMA Clinical Research Warren
    Warren Township, New Jersey 07059, United States
  • NYU Langone Health
    New York, New York 10016, United States
  • Centricity Research Columbus Ohio Multispecialty
    Columbus, Ohio 43213, United States
  • DM Clinical Research - Philadelphia
    Philadelphia, Pennsylvania 19107, United States
  • Clinical Neuroscience Solutions Inc.
    Memphis, Tennessee 38119, United States
  • DM Clinical Research - Bellaire
    Houston, Texas 77081, United States
  • SMS Clinical Research
    Mesquite, Texas 75149, United States
  • IMA Clinical Research San Antonio
    San Antonio, Texas 78229, United States
  • DM Clinical Research - Sugar Land
    Sugar Land, Texas 77478, United States
  • Clinical Research Puerto Rico
    San Juan, 00909, Puerto Rico
08

References and documents

Individual participant data

Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

Data sharing details ↗ · www.pfizer.com

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Apr 2025 to primary completion in Sep 2025, 5 months.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 17, 2025
First posted
Mar 24, 2025
StartActual
Apr 4, 2025
Primary completionActual
Sep 30, 2025
CompletionActual
Sep 30, 2025
Last update
Nov 6, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 6, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06890416
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Mar 24, 2025
Start date
Apr 4, 2025
Primary completion
Sep 30, 2025
Completion
Sep 30, 2025
Last update
Nov 6, 2025

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Abrysvo

Start the discussion